re: isn't it time? - time for what ?
Oh, being a long term investor vs being an impatient speculator can be so tricky. Suggest it would be good to keep the interchange and expectations relevant. Reading - no make that studying - the media releases from Ventracor should help put things into perspective.
Visit this site for latest information available to the public http://www.ventracor.com/
Start with this one and remember these things do not always stick to a fixed time plan: ======================================= Company Announcement
Ventracor Artificial Heart Pilot Trial Update
VENTRACOR LIMITED 2003-04-23 ASX-SIGNAL-G
HOMEX - Brisbane +++++++++++++++++++++++++ Ventracor Limited (ASX:VCR), today provided a progress repor t on the Pilot Trial of the VentrAssist(TM)artificial heart at The Alfred hospital in Melbourne.
The company said Pilot Tr ial preparations were on track and had entered their final stages. Ventracor Managing Director and Chief Executive Officer, Mr Michael Spooner, said that at a meeting with the medical investigative team at The Alfred hospital yesterday, Ventracor introduced an updated and improved ser ies of Data Collection Forms. He said these forms would provide a basis for Pilot Tr ial data to be collected as well as suppor ting the global Pivotal Trial.
"This integrated approach may well provide Ventracor with significant overall time savings in our race to obtain global regulatory approval to sell the VentrAssist(TM) device.
"In effect, Ventracor is looking to incorporate Pilot Trial data into our global Pivotal Tr ial submissions, a process that has only become possible as a result of international developments in the past few weeks.
"Ventracor key staff are working closely with the medical investigative team at The Alfred hospital in Melbourne to facilitate the implementation of the additional requirements in the new Data Collection Forms.
"Ventracor is also assisting with the introduction of new clinical tools which monitor patient condition and rehabilitation. These tools will help in proving that the VentrAssist(TM) is the treatment of choice for patients with severe heart failure.
"We are expecting the medical investigative team to finalise recruitment of patients dur ing May with the first implant to be performed in June.
"Ventracor will utilize this per iod of time to under take additional rigorous testing of the final devices.
"We are delighted with the outcomes from our preclinical testing and want to take every oppor tunity to ensure the success of the overall trial process.
"Both Ventracor and The Alfred hospital are doing their utmost to ensure patient wellbeing, dignity and privacy remain our primary concern", Mr Spooner said.
For more information, please contact:
Michael Spooner Julie Meldrum MANAGING DIRECTOR & CEO CORPORATE COMMUNICATIONS MANAGER 02 9406 3100 02 9406 3100 or 0419 228 128
.
VCR Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.